Effects of a 4-week treatment with 500 μg roflumilast on exhaled NO, pulmonary function and other inflammatory indices in patients with asthma

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A phase 3, double-blind, randomized, placebo-controlled, two-period crossover study with a single-blind placebo baseline period in subjects with asthma.